

Detection of *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} genes among the Extended-Spectrum β -Lactamases (ES β Ls) producing *Enterobacteriaceae* isolated from hospital-acquired infections and community in Egypt.

Mohamad Saleh Sadek,¹ MSc, Gamal M. El-Sherbiny,^{1*} PhD, Mona M. A. Halim,² PhD,

Amr Fouda,¹ PhD.

* Corresponding Author:

Gamal M. El-Sherbiny

gamalelsherbiny1970@yahoo.com

Received for publication February 11, 2021; Accepted April 9, 2021; Published online April 9, 2021.

Copyright 2020 The Authors published by Al-Azhar University, Faculty of Medicine, Cairo, Egypt. All rights reserved. This an open-access article distributed under the legal terms, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

doi: 10.21608/aimj.2021.61624.1412.

¹Botany and Microbiology Department, Faculty of Science, Al-Azhar University.

²Clinical Pathology Department, Faculty of Medicine, Cairo University.

ABSTRACT

Background: Bacteria are resistant to an antibiotic such as *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter* sp. responsible for morbidity in worldwide. ES β Ls are a group of plasmids encoded enzymes that have the efficacy to hydrolyze β -lactams antibiotics. The spread of (ES β Ls) representing a serious problem and threatening the ability to treat an infection.

Aim of the study: This study aimed to investigate ES β Ls-producing *Enterobacteriaceae* sp. isolated from patients and healthy individuals and detect the resistant genes *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}.

Patients and Methods: Two hundred bacterial isolates were recovered from patients and healthy individuals rectal swab samples. These isolates were screened for producing ES β Ls and identified using both standard bacteriological methods and VITEK2 compact system). The antibiotics resistance of *Enterobacteriaceae* was assessed by the disk diffusion method and detection of *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} genes by multiplex PCR.

Results: Two hundred *Enterobacteriaceae* screening for-producing ES β Ls showed that 56% (112/200) produce ES β Ls. One hundred and twelve ES β Ls-*Enterobacteriaceae* identified as following, *Klebsiella pneumoniae* 51.73% (58/112), *Escherichia coli* and 46.40% (52/112), and *Enterobacter cloacae* 1.80% (2/112). The antibiotic resistance patterns of *Enterobacteriaceae* showed high resistance to ciprofloxacin, levofloxacin, and amikacin with the ratio of (71.76%), (60.72%) and (60.72%), respectively. Furthermore, ES β Ls *Enterobacteriaceae* harbored genes *bla*_{CTX-M} (78.6%), *bla*_{TEM} (73.2%) and *bla*_{SHV} (68.75%). The *bla*_{TEM} was found the predominant gene in *E. coli* isolates 80.8%, while *bla*_{CTX-M} in *Klebsiella pneumoniae* 81%.

Conclusion: The present study showed a significant distribution of multidrug-resistant ES β Ls-producing *Enterobacteriaceae* in patients in the hospital- and community-acquired rectal infection. ES β Ls-producing *Enterobacteriaceae* species harboring co-existence resistant genes.

Keywords: *Enterobacteriaceae*; ES β Ls; resistance genes.

Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

Authorship: All authors have a substantial contribution to the article.

INTRODUCTION

Bacteria are resistant to an antibiotic such as *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter* sp. responsible for morbidity in worldwide¹. Antibiotics resistance due to extended-spectrum β -lactamases (ES β Ls) was firstly recorded in 1979 in Europe². ES β Ls are a group of plasmids encoded enzymes that have the efficacy to hydrolyze β -lactams antibiotics³. It was firstly reported that ES β Ls producers are predominantly belonging to *E. coli* and *Klebsiella*⁴

Among several enzymes' linkage with ES β Ls activity, ES β Ls class A include on cefotaximase (CTX-M), Temoneira (TEM), and SHV (to sulfhydryl variable active site)³. These genes are commonly in *Klebsiella pneumoniae* and *E. coli*⁵. Investigation of these genes is important not only for their ability to hydrolyze β -lactam antibiotics but also because the plasmids responsible for ES β Ls production regularly harboring genes encoding resistance to other antibiotic groups like aminoglycosides and fluoroquinolones. A previously

published study by Hassan *et al.*, 2012 reported 98% of 65 *Klebsiella pneumoniae* isolates obtained from Egyptian patient samples harbor SHV gene while 11% harbor CTX-M gene⁶. In another study conducted in Egypt highlighted that the CTX-M gene is the predominant resistance gene in ESβLs *Enterobacteriaceae*⁷. To date, few published studies were concerned with the assessment of ESβLs resistant genes in *Enterobacteriaceae* strains of the hospital and community setting. Therefore, this study aimed to isolate *Enterobacteriaceae* producing ESβLs species from rectal swab samples, antibacterial resistance pattern and determine the predominate ESβLs resistance gene in isolates of hospital settings versus the presence of those genes in rectal isolates from community settings

PATIENTS AND METHODS

Samples collection

One hundred rectal swab samples were collected from 50 patients (two samples taken from each patient, one upon admission and second after 48h of admission) at Abu El-Reesh Pediatric Hospital, Cairo University Hospital, Egypt, and one hundred rectal swab samples from healthy individuals duration period extending from December 2016 to December 2019.

Cultivation and isolation of bacterial species

Rectal swab samples were cultivated on MacConkey media and incubated for 24 hours at 37°C aerobically. Colonies with positive lactose fermentation (Pink colonies) were collected. The pure cultures were identified based on morphological, physiological, and biochemical characteristics using microbiological methods^{8th},⁸ Bergey's Manual of Systematic Bacteriology⁹. Isolates identification was confirmed by the VITEK2

compact system (Biomérieux Inc., Marcy l'Etoile, France).

Screening of (ESβLs) production

The antibiotics synergy of ESβLs producing bacteria was detected by the double-disk synergy test (DDST)¹⁰. Bacterial colonies from MacConkey agar equivalent to 0.5 McFarland are cultured on Mueller-Hinton agar media. The following antibiotic discs are used, cefotaxime 30µg/ml, ceftazidime 30µg/ml (third-generation cephalosporins), and amoxicillin/clavulanate 20/10µg/ml. Culturing plates were incubated at 35°C for 24h. ESβLs production activity is confirmed if there is an extension of the inhibition zone between any of the cephalosporins and amoxicillin-clavulanate disk (D-shape or keyhole shape)^{11,12}.

Antibiotic resistance pattern

Antibacterial sensitivity testing was carried out by disc diffusion method and the results were expressed as resistant, intermediate, or susceptible according to CLSI guidelines¹⁰. The antibiotics used in this study belonging to four groups antibiotics carbapenems include on (imipenem 10µg and meropenem 10µg), aminoglycosides (gentamicin 10µg/ml and amikacin 30µg/ml), fluoroquinolones (ciprofloxacin 5µg/ml and levofloxacin 5µg/ml), and polypeptides (colistin 10µg/ml and polymyxin B 300U/ml).

Molecular detection of *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} genes using PCR.

A total of 120 ESβLs producing *Enterobacteriaceae* were investigated for detecting three genes (*bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}) using multiplex PCR and specific primers (Table 1). The detection methods were designed according to the methods Randall *et al.*, 2009¹³.

Gene type	Primer sequence (5'-3')	Gene product length (bp)	Reference
TEM F	TCGTGTCGCCCTTATTCCCTTTTT	426	[19]
TEM R	GCGGTTAGCTCCTCCGGTCCTC		
SHV F	GTGGATGCCGGTGACGAACAGC	212	
SHV R	TGGCGCAAAAAGGCAGTCAATCCT		
CTX-M F	CGCTTTGCGATGTGCAG	551	[8]
CTX-M R	ACCGCGATATCGTTGGT		

Table 1. Primer sets used in PCR runs for tested isolates.

Statistical analysis:

The data were subjected to analysis of variance (ANOVA) by statistical package SPSS v17. The mean difference comparison between the treatments was analyzed by the Tukey HSD test at a significance level of $P \leq 0.05$.

RESULTS

Screening of ESβLs producing *Enterobacteriaceae*

A total of 200 *Enterobacteriaceae* were screening for producing ESβLs, the results obtained showed that 112 (56%) bacterial isolates producing ESβLs. Thirty-two isolates (64%) from patients upon admission, 40 (80%) from the same patients after 48h of admission, and 40 (40%) from healthy individuals.

identification of ESβLs *Enterobacteriaceae*

The results revealed that 112 bacterial isolates producing ESβLs (32 isolates from patients upon admission, 40 from same patients after 48h of admission, and 40 from healthy individuals) were

included to identify. The results obtained from morphological, physiological, and biochemical tests revealed that 100% of bacterial isolates are Gram-negative, rod shape, motile, ferment lactose sugar in MacConkey agar, and positive results in the triple sugar iron (TSI) test. Only 46.4% (52/112) from bacterial isolates have the ability to utilizing tryptophan and forming indole and produce decarboxylase enzyme. Moreover, 1.8% (2/112), 51.73% (58/112), and 53.5(60/112) can produce H_2S , urease, and citrate utilization respectively (Table 2). According to results obtained from the identification of 112 ESBLs - producing *Enterobacteriaceae* species, the most common species was found

Klebsiella pneumonia followed by *E. coli* and *Enterobacter cloacae* with percent 51.8% (58/112), 46.4% (52/112), and 1.8% (2/112), respectively. This result was confirmed by VITEK-2 with an echelon ratio of 99%. In this study, The identification of bacterial species isolated from healthy individuals revealed that the most common species *E. coli* 22.3% (25/112) followed by *Klebsiella pneumonia* 13.38% (15/112), comparable isolates from patients the most common species were found *Klebsiella pneumonia* 38.35% (43/112) followed by *E. coli* 24% (27/112) and 1.8% (2/112) *Enterobacter cloacae*.

Bacterial strains	Health	patient		Total	%	Biochemical test						
		1 st samples	2 nd samples			motility	TSI	H ₂ S	Urease	Citrate utilization	Indole	Decarboxylase enzyme
<i>E. coli</i>	25	15	12	52	46.40%	+	+	-	-	-	+	+
<i>K. pneumonia</i>	15	16	27	58	51.73%	+	+	-	+	+	-	-
<i>Enterobacter cloacae</i>	0	1	1	2	1.80%	+	+	+	-	+	-	+
Total	40	32	40	112	100%	--	--	--	--	--	--	--

Table 2: Identifications of 112 ESBLs producing *Enterobacteriaceae* species isolated from patients and healthy individuals.

Resistance patterns of *Enterobacteriaceae*

The antibiotic profile of *Enterobacteriaceae* isolated from patients showed the highest resistance to ciprofloxacin, levofloxacin, and amikacin (71.76%), (60.72%) and (60.72%), while, they were sensitive to colistin, polymyxin, meropenem, and imipenem (95.22%), (95.22%) (44.16%), and (44.16%), respectively. Moreover, it was noted that bacterial species isolated from patients after 48h of admission highly resistant to bacterial species isolates from the same patients upon admission and healthy individuals (Table 3). *E. coli* isolated from patients after 48hours of admission showed the highest resistance to ciprofloxacin, levofloxacin 91.63%, while, isolates from patients upon admission 66.6%. However, *E. coli* isolated from healthy individuals exhibit a low resistance level (Table 4). In *K. pneumoniae*, from patients after 48hours of admission the highest resistance was observed against and ciprofloxacin, levofloxacin 81.4% with a low resistance level to polymyxin B and colistin 3.70%. (Table 5). *Enterobacter cloacae* recorded the highest resistance to ciprofloxacin, levofloxacin with 100%. *K. pneumoniae* showed the resistance to meropenem and imipenem with 53.32%, 51.6%, followed by *Enterobacter cloacae* 50.0% and *E. coli* with 23.04%, respectively (table 4 and 5). Overall, *K. pneumoniae* showed the highest resistance level from *E. coli* isolates (Table 6).

Prevalence of *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} genes in *Enterobacteriaceae* species

In our study, 88/112 (78.5%) isolates it has *bla*_{CTX-M} resistant gene, 82/112(73.2%) *bla*_{TEM} gene and 77/112 (68.70%) *bla*_{SHV} (table 7) Figure 1A, 1B, 2A and 2B.

The statistical analysis revealed that no significant statistical difference between the presence resistant genes *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} in healthy individuals isolates comparable with isolates collected from patients either upon admission or after 48h. of admissions. Also, the difference between the presences of the three genes in bacterial isolates collected from patients cases either upon admission or after 48h of admission was statistically insignificant (Table 8). Interestingly, the predominant resistant gene in bacterial species isolated from patients and healthy individuals is the *bla*_{CTX-M} gene followed by *bla*_{TEM} and *bla*_{SHV} (Table 8). *bla*_{CTX-M} was the predominant gene in *Klebsiella pneumonia* isolates (81.0%) while it was the second common in *E. coli* isolates (75.0%). The *bla*_{CTX-M} resistance gene was the predominant gene in *E. coli* isolates (80.8%), and the least gene in *Klebsiella pneumonia* isolates (67.2%), *bla*_{SHV}, a second common gene in *Klebsiella pneumonia* (79.3%) (Table 9).

Antibiotic	Inpatients (72 isolates)						Healthy individual (40 isolates)		
	Upon admission (32 isolates)			After 48h of admission (40 isolates)			Resistant	Intermediate	Sensitive
	Resistant	Intermediate	Sensitive	Resistant	Intermediate	Sensitive			
Amikacin	16 (50%)	0(0%)	16 (50%)	27(67.5%)	0 (0%)	13 (32.5%)	6 (15%)	2 (5%)	32 (80%)
Gentamicin	16 (50%)	0(0%)	16 (50%)	27(67.5%)	0 (0%)	13 (32.5%)	8 (20%)	0(0%)	32 (80%)
Ciprofloxacin	20 (62.5%)	0(0%)	12 (37.5%)	33(82.5%)	1 (2.5%)	6 (15%)	4 (10%)	2 (5%)	34 (85%)
Levofloxacin	20 (62.5%)	0(0%)	12 (37.5%)	33(82.5%)	0 (0%)	7 (17.5%)	6 (15%)	0 (0%)	34 (85%)
Polymyxin B	2 (6.25%)	0(0%)	30(93.75%)	1 (2.5%)	0 (0%)	39 (97.5%)	1 (2.5%)	0(0%)	39 (97.5%)
Colistin	2 (6.25%)	0(0%)	30(93.75%)	1 (2.5%)	0 (0%)	39 (97.5%)	1 (2.5%)	0 (0%)	39 (97.5%)
Meropenem	14(43.75%)	0(0%)	18(56.25%)	26 (65%)	0 (0%)	14 (35%)	2 (5%)	1 (2.5%)	37 (92.5%)
Imipenem	14(43.75%)	0(0%)	18(56.25%)	26 (65%)	0 (0%)	14 (35%)	3 (7.5%)	0 (0%)	37 (92.5%)

Table 3: Antibiotic resistance pattern of 112 ESβLs producing *Enterobacteriaceae* species.

Antibiotics	Patients						Healthy individuals		
	Upon admission			After 48h of admission			R (%)	I (%)	S (%)
	R (%)	I (%)	S (%)	R (%)	I (%)	S (%)			
Amikacin	46.62%	0.0%	53.28%	58.31%	0.0%	41.65%	12.0%	8.0%	80.0%
Gentamicin	46.62%	0.0%	53.28%	58.31%	0.0%	41.65%	20.0%	0.0%	80.0%
Ciprofloxacin	66.6%	0.0%	33.3%	91.63%	0.0%	8.33%	8.0%	0.0%	92.0%
Levofloxacin	66.6%	0.0%	33.3%	91.63%	0.0%	8.33%	8.0%	0.0%	92.0%
Polymyxin B	6.6%	0.0%	93.24%	0.0%	0.0%	100%	0.0%	0.0%	100%
Colistin	6.6%	0.0%	93.24%	0.0%	0.0%	100%	0.0%	0.0%	100%
Meropenem	26.64%	0.0%	73.26%	50.0%	0.0%	50.0%	4.0%	0.0%	96.0%
Imipenem	26.64%	0.0%	73.26%	50.0%	0.0%	50.0%	4.0%	0.0%	96.0%

Table 4: Antibiotics resistance pattern of *E. coli* R= Resistant, I= Intermediate, S= Sensitive.

Antibiotics	Patients						Healthy individuals		
	Upon admission			After 48h of admission			R (%)	I (%)	S (%)
	R (%)	I (%)	S (%)	R (%)	I (%)	S (%)			
Amikacin	56.25%	0.0%	43.75%	70.4%	0.0%	29.6%	20.0%	0.0%	80.0%
Gentamicin	56.25%	0.0%	43.75%	70.4%	0.0%	29.6%	20.0%	0.0%	80.0%
Ciprofloxacin	62.5%	0.0%	37.5%	81.4%	3.70%	14.8%	13.32%	13.32%	73.26%
Levofloxacin	62.5%	0.0%	37.5%	81.4%	0.0%	18.5%	26.64	0.0%	73.26%
Polymyxin B	6.25%	0.0%	93.75%	3.70%	0.0%	96.2%	6.66%	0.0%	93.24%
Colistin	6.25%	0.0%	93.75%	3.70%	0.0%	96.2%	6.66%	0.0%	93.24%
Meropenem	62.5%	0.0%	37.5%	70.3%	0.0%	29.6%	6.66%	6.66%	86.58%
Imipenem	62.5%	0.0%	37.5%	70.3%	0.0%	29.6%	13.32%	0.0%	86.58%

Table 5: Antibiotics resistance pattern of *Klebsiella pneumoniae* R= Resistant, I= Intermediate, S= Sensitive.

Antibiotics	<i>E. coli</i> 52 isolates			<i>K. pneumonia</i> 58 isolates			<i>Enterobacter cloacae</i> 2 isolates		
	R (%)	I (%)	S (%)	R (%)	I (%)	S (%)	R (%)	I (%)	S (%)
Amikacin	32.64	3.84%	63.36%	53.32%	0.0%	46.44%	50.0%	0.0%	50.0%
Gentamicin	36.48%	0.0%	63.36%	53.32%	0.0%	12.04	50.0%	0.0%	50.0%
Ciprofloxacin	44.16%	0.0%	55.65%	58.48%	5.16%	36.12%	100%	0.0%	0.0%
Levofloxacin	44.16%	0.0%	55.65%	61.92%	0.0%	37.84%	100%	0.0%	0.0%
Polymyxin B	1.92%	0.0%	97.92%	5.16%	0.0%	94.6%	0.0%	0.0%	100%
Colistin	1.92%	0.0%	97.92%	5.16%	0.0%	94.6%	0.0%	0.0%	100%
Meropenem	23.04%	0.0%	78.72%	51.6%	1.72%	46.44%	50.0%	0.0%	50.0%
Imipenem	23.04%	0.0%	78.72%	53.32%	0.0%	46.44%	50.0%	0.0%	50.0%

Table 6: Antibiotics resistance pattern of total *E. coli*, *Klebsiella pneumonia*, and *Enterobacter cloacae*. R= Resistant, I= Intermediate, S= Sensitive

Resistant gene	Number of isolates containing each gene	Percentage
<i>bla</i> _{CTX-M}	88 bacterial isolates	78.6%
<i>bla</i> _{TEM}	82 bacterial isolates	73.2%
<i>bla</i> _{SHV}	77 bacterial isolates	68.75%

Table 7: Summary of prevalence *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV} genes in the 112 ES β LS producing *Enterobacteriaceae* species.

Resistant genes		Patients		Healthy individuals	Total
		Upon admission	After 48h of admission		
No gene	-----	2	3	2	7
One gene	<i>bla</i> _{CTX-M}	1	0	3	4
	<i>bla</i> _{TEM}	3	1	3	7
	<i>bla</i> _{SHV}	1	1	2	4
Two genes	<i>bla</i> _{CTX-M} + <i>bla</i> _{TEM}	5	4	7	16
	<i>bla</i> _{CTX-M} + <i>bla</i> _{SHV}	4	5	5	14
	<i>bla</i> _{TEM} + <i>bla</i> _{SHV}	0	2	4	6
Three genes	<i>bla</i> _{CTX-M} + <i>bla</i> _{TEM} + <i>bla</i> _{SHV}	16	24	14	54
Total		32	40	40	112

Table 8: Distribution of *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV} genes in ES β LS producing *Enterobacteriaceae* species.

Resistant genes	<i>E. coli</i> (total 52 isolates)		<i>Klebsiella pneumonia</i> (total 58 isolates)		<i>Enterobacter cloacae</i> (total 2 isolates)	
	Number of isolates	Percentage %	Number of isolates	Percentage %	Number of isolates	Percentage %
<i>bla</i> _{CTX-M}	39	75%	47	81%	2	100%
<i>bla</i> _{TEM}	42	80.8%	39	67.2%	2	100%
<i>bla</i> _{SHV}	30	57.7%	46	79.3%	2	100%

Table 9: Distribution of *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV} genes in ES β LS-producing *Enterobacteriaceae*.




Fig 1A: Detection of genes *bla*_{TEM} and *bla*_{SHV} in 12 isolates ESβLs-producing *E. coli* by PCR, 426 bp PCR product of *bla*_{CTX-M}, and 212 bp of *bla*_{SHV}. Lane M: ladder. Lanes 1,2 no *bla*_{TEM} and Lane 6: *bla*_{SHV}, while lanes 3, 4, 5, 7, 8,9, 10, 11 and 12 contain *bla*_{TEM} and *bla*_{SHV} genes



Fig 1B: Detection of gene *bla*_{CTX-M} in 12 isolates ESβLs-producing *E. coli* by PCR, 551 bp PCR product of *bla*_{CTX-M}. Lane M ladder, lanes 9 no *bla*_{CTX-M}. while Lanes 1, 2, 3, 4, 5, 6, 7, 8, 10, 11,12 and 13 contains the *bla*_{CTX-M} gene.




Fig 2A: Detection of genes *bla*_{TEM} and *bla*_{SHV} in 12 isolates ESβLs-producing *Klebsiella pneumoniae* by PCR, 426 bp PCR product of *bla*_{CTX-M}, and 212 bp of *bla*_{SHV}. Lane M: ladder. Lanes 1,2 no *bla*_{TEM} and Lane 6: *bla*_{SHV}, while lanes 3, 4, 5, 7, 8,9, 10, 11 and 12 contain *bla*_{TEM} and *bla*_{SHV} genes.




Fig 2B: Detection of gene *bla*_{CTX-M} in 12 isolates ESβLs-producing *Klebsiella pneumoniae* by PCR, 551 bp PCR product of *bla*_{CTX-M}. Lane M ladder, lanes 2 and 12 no *bla*_{CTX-M}. while Lanes 3, 4, 5, 6, 7, 8, 9, 10, 11 and 13 contains the *bla*_{CTX-M} gene.

DISCUSSION

In the last years, ESβLs producing *Enterobacteriaceae* have been increasingly recognized in hospitals in Egypt and, unfortunately, are linkage with multiple drug resistance¹⁴. The prevalence of producing ESβLs- *Enterobacteriaceae* was found to be (56%) 112/200, comparable with a studies from Ghana (49.3%)¹⁵, Ethiopia (57.6%)¹⁶,

India (57.5%)¹⁷, Burkina Faso (58.0%)¹⁸, and Uganda (62.0%)¹⁹. Teklu et al., 2019 recorded 57.7% (246/426) from *Enterobacteriaceae* species isolated from clinical samples producing ESβLs²⁰. A current study from Turkey recorded a prevalence rate of ESβLs- *Enterobacteriaceae* carriage (34.3%) in the community²¹. The predominate ESβLs production was observed in *Klebsiella pneumoniae*, these results agree with Teklu et al., 2019²⁰. In this study, the antibiotics resistance patterns of ESβLs-producing *Enterobacteriaceae* species isolated from patients showed that highly resistant level to ciprofloxacin, levofloxacin, and amikacin (71.76%), (60.72%) and (60.72%), while, they were sensitive to colistin, polymyxin, meropenem and imipenem (95.22%), (95.22%) (44.16%) and (44.16%), respectively. Teklu et al., 2019 isolated *Enterobacteriaceae* producing ESβLs from clinical samples resistant to norfloxacin with ratio (58.8%), ciprofloxacin (46.3%), gentamycin (43.4%), but low resistance to meropenem (5.2%) and amikacin (13.8%)²⁰. The studies were conducted in Burkina which showed that 89% of ESβLs-producer isolates non-susceptible to gentamicin and 80% to ciprofloxacin²². In Ghana, 91.2% of ESβLs - producer *Enterobacteriaceae* was found resistant to gentamicin and 41.1% to ciprofloxacin²³. In central India 50% from ESβLs -producer *Enterobacteriaceae* resistant to gentamicin and 87.5% to ciprofloxacin²². While in Nepal 90.7% resistant to ciprofloxacin, 90.4 and, 63.12% to gentamicin²⁴. In this study, *E. coli* isolates from patients after 48hours of admission showed the highest resistance rate to ciprofloxacin, levofloxacin 91.63%, while isolates from patients upon admission showed a resistance rate of 66.6%. Several studies showed that *E. coli* isolates exhibit a resistance rate to ciprofloxacin and levofloxacin 86.6%²⁵. Zheng and Xiang-zhu, 2017 reported a resistance rate to ciprofloxacin and levofloxacin among *E. coli* isolates 85.08% and 80.42%, respectively²⁶. In the current study *Klebsiella pneumoniae* isolated from patients after 48hours of admission showed a resistance rate to ciprofloxacin, levofloxacin 62.5%. Zheng and Xiang-zhu, 2017 reported that *Klebsiella pneumoniae* resistant to ciprofloxacin, levofloxacin with a rate of 66.86%, and 50.0%, respectively²⁶. In our study *K. pneumoniae* showed the highest resistance to meropenem and imipenem 53.32%, 51.6%, followed by *Enterobacter cloacae* 50.0% and *E. coli* with 23.04%, and all producing ESβLs-*Enterobacteriaceae* showed a resistance rate to imipenem and meropenem 37.46% (42/112) and 36.57% (41/112), respectively. This finding disagrees with Teklu et al., 2019, which found producing ESβLs-*Enterobacteriaceae* resistant to meropenem 5.2%, *E. coli* (3.5%), and *K. pneumoniae* 10.7%²⁰.

Prevalence of resistance genes *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} in ESβLs producing *Enterobacteriaceae* species

In the current study, the predominant resistant gene was *bla*_{CTX-M}78.6% followed by *bla*_{TEM} 73.2%, and *bla*_{SHV} 68.75%. These results are in agreement with several studies^{27, 28, 29} which indicate that dissemination of the *bla*_{CTX-M} gene represents a

global pandemic. The multinational survey performed by Ben-Ami *et al.*, 2009 concluded that the *bla*_{CTX-M} gene was predominant in *E. coli* while the *bla*_{TEM} was predominant in *Klebsiella pneumoniae*³⁰. This result was not matched with our study, where the *bla*_{TEM} was predominate in *E. coli* while *bla*_{TEM} in *Klebsiella*. In our study, some ES β LS producing *Enterobacteriaceae* species harboring more than one resistant gene this result agreement with Zhao *et al.*, 2015 and Bajpai *et al.*, 2017^{31, 32}. The presence of more than one resistant gene could be attributed to the participation of genetic elements in the mobilization of these genes³³. A low number of ES β LS producer isolates were not harboring one resistant gene at least from *bla*_{CTX-M}, *bla*_{TEM}, and *bla*_{SHV}, a similar result was reported by Bajpai *et al.*, 2017³². In the same regard, the statistical analysis showed that the difference in the presence of the three ES β LS encoding genes in healthy individuals versus their presence in patient samples was not statistically significant. The presence of three resistance genes (*bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}) in ES β LS-producing *Enterobacteriaceae* species illustrate the genetic diversity among isolates due to horizontal gene transfer between different bacterial species.

In this study, the *bla*_{CTX-M} gene was predominant in bacterial species isolated from patient samples upon a and after 48h of admission with a percentage of 81.25% (26/32) and 82.5 (33/40), respectively. This result agreed with Hagel *et al.*, 2019²⁹, who reported that *bla*_{CTX-M} was represented in 81.1% of upon admission isolates and 84.1% of discharge isolates. Moreover, Pérez *et al.*,³⁴ showed that the *bla*_{CTX-M} gene represents 83.17% of all isolates taken from patients upon admission. Data analysis of healthy individuals revealed that the *bla*_{CTX-M} resistant gene was the most common gene detected in 72.5% of bacterial isolates. Also, the *bla*_{SHV} gene was detected in 62.5% of the healthy individuals bacterial isolates. In the same regard, Valverde *et al.*, 2004 reported that 70% of the non-hospitalized individual were colonized with ES β LS carrying the *bla*_{CTX-M} gene³⁵. The predominance of a *bla*_{CTX-M} gene in *E. coli* clinical patients isolates was also reported by Ahmed *et al.*, 2014³⁶. As well as, *bla*_{CTX-M} encoding ES β LS gene was detectable in 96.6% of community isolates³⁷.

CONCLUSION

From this study we can be concluded, ES β LS producing *Enterobacteriaceae* species are carried by patients and healthy individuals in the community. Fecal carriage of resistant *Enterobacteriaceae* species represents a high risk for spread multidrug resistance bacteria. ES β LS producing *Enterobacteriaceae* harboring co-existence resistant genes. The best choice for the treatment of ES β LS *Enterobacteriaceae* is polymyxin B and colistin. To prevent further spread ES β LS producing *Enterobacteriaceae*, it should be motivating the ideal use of antibiotics, and antibiotic resistance should keep under surveillance in Egypt.

REFERENCES

1. Belete MA and Saravanan M. A Systematic Review on Drug-Resistant Urinary Tract Infection Among Pregnant Women in Developing Countries in Africa and Asia; 2005–2016. *Infection and Drug Resistance*. 2020;13:1465-77.
2. Livermore D and Hawkey P. CTX-M: changing the face of ESBLs in the UK. *Journal of Antimicrobial Chemotherapy*. 2005;56(3):451.
3. Saravanan M, Ramachandran B and Barabadi H. The prevalence and drug resistance pattern of extended-spectrum β -lactamases (ESBLs) producing *Enterobacteriaceae* in Africa. *Microbial Pathogenesis*. 2018;114:180-92.
4. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *Clinical Infectious Diseases*. 2001;32(8):1162-71.
5. Bradford PA. Extended-Spectrum β -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clinical Microbiology Reviews*. 2001;14(4):933-51.
6. Hassan W, Hashim A and Domany R. Plasmid-mediated quinolone resistance determinants qnr, aac (6')-Ib-cr, and qep in ES β LS producing *Enterobacteriaceae* -producing *Escherichia coli* clinical isolates from Egypt. *Indian journal of medical microbiology*. 2012;30(4):442.
7. Fam N, Leflon-Guibout V, Fouad S, et al. CTX-M-15-producing *Escherichia coli* clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital settings. *Microbial drug resistance*. 2011;17:67-73.
8. Collins HC, Lyne MP, Grange JM, et al. *Microbiological Methods*. 8th ed. Arnold, 338 Euston Road, London NW1 3BH: Arnold; 2004.
9. Garrity G, Bell J and Lilburn T. Bergey's manual of systematic bacteriology. 2005. Phylum BVI Phylum BVI Chloroflexi phy nov.427-46.
10. Clinical and Laboratory Standards Institute CLSI (2018) Performance standards for antimicrobial susceptibility testing; 28th ed Informational Supplement. CLSI document M100-S28. Clinical and Laboratory Standards Institute, Pennsylvania.
11. Drieux L, Brossier F, Sougakoff W, et al. Phenotypic detection of extended β -spectrum β -lactamase production in *Enterobacteriaceae*: review and bench guide. *Clinical Microbiology and Infection*. 2008;14:90-103.
12. Saxena SK. Trends in Infectious Diseases. BoD-Books on Demand; 2014.
13. Randall L, Kirchner M, Teale C, et al. Evaluation of CHROMagar CTX, a novel medium for isolating CTX-M-ESBL- positive *Enterobacteriaceae* while inhibiting AmpC-producing strains. *Journal of Antimicrobial Chemotherapy*. 2009;63(2):302-308.
14. Knudsen PK, Brandtzaeg P, Høiby EA, Bohlin J, Samuelsen Ø, Steinbakk M, et al. Impact of extensive antibiotic treatment on the fecal carriage of antibiotic-resistant enterobacteria in

- children in a low resistance prevalence setting. *PLoS One*. 2017;12:187618.
15. Obeng-Nkrumah N, Twum-Danso K, Krogfelt KA, et al. High levels of extended- Spectrum Beta-lactamases in a major teaching Hospital in Ghana: the need for regular monitoring and evaluation of antibiotic resistance. *Am J Trop Med Hyg*. 2013;89(5):960–4.
 16. Abera B, Kibret M and Mulu W. Extended-spectrum beta-lactamases and antibiogram in Enterobacteriaceae from clinical and drinking water sources from Bahir Dar city, Ethiopia. *PLoS One*. 2016;11(11):1–10.
 17. Rao SP, Rama PS, Gurushanthappa V, et al. Extended-Spectrum Beta-lactamases producing *Escherichia coli* and *Klebsiella pneumoniae*: a multi-centric study across Karnataka. *J Lab Physicians*. 2014;6(1):7–13.
 18. Ouedraogo A-S, Sanou M, Kissou A, et al. High prevalence of extended-spectrum β -lactamase producing Enterobacteriaceae among clinical isolates in Burkina Faso. *BMC Infect Dis*. 2016;16(1):326
 19. Kateregga JN, Kantume R, Atuhaire C, et al. Phenotypic expression and prevalence of ESBL-producing Enterobacteriaceae in samples collected from patients in various wards of Mulago hospital. *Uganda BMC Pharmacol Toxicol*. 2015;16(14):1-6.
 20. Teklu DS, Abebe AN, Melese HL, et al. Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia. *Antimicrob Resist Infect Control*. 2019; 8: 39.
 21. Hazirolan G, Mumcuoglu I, Altan G, et al. Fecal carriage of extended-spectrum beta-lactamase and AmpC beta-lactamase-producing Enterobacteriaceae in a Turkish community. *Niger J Clin Pract*. 2018;21:81–6.
 22. Ouedraogo A-S, Sanou M, Kissou A, Sanou S, Solaré H, Kaboré F, et al. High prevalence of extended-spectrum β -lactamase producing Enterobacteriaceae among clinical isolates in Burkina Faso. *BMC Infect Dis*. 2016;16(1):326.
 23. Obeng-Nkrumah N, Twum-Danso K, Krogfelt KA, et al. High levels of extended-Spectrum Beta-lactamases in a major teaching Hospital in Ghana: the need for regular monitoring and evaluation of antibiotic resistance. *Am J Trop Med Hyg*. 2013;89(5):960–4.
 24. Fam N, Leflon-Guibout V, Fouad S, et al. CTX-M-15-producing *Escherichia coli* clinical isolates in Cairo (Egypt). *Microb Drug Resist*. 2011; 17(1):67–73
 25. Yingmei F, Wenli Z, Hong W, et al. Specific patterns of *gyrA* mutations determine the resistance difference to ciprofloxacin and levofloxacin in *Klebsiella pneumoniae* and *Escherichia coli*. *BMC Infect Dis*. 2013; 13: 8
 26. Zheng F and Xiang-zhu M. Research on pathogenic bacteria and antibiotic resistance of Enterobacteriaceae in hospitalized elderly patients. *Biomedical Research*. 2017; 28(16): 7243-7.
 27. Leski TA, Taitt CR, Bangura U, et al. High prevalence of multidrug-resistant Enterobacteriaceae isolated from outpatient urine samples but not the hospital environment in Bo, Sierra Leone. *BMC Infect Dis*. 2016;16:167.
 28. Alves M and Lemire A, Decré D, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in the intensive care unit: acquisition does not mean cross-transmission. *BMC infectious diseases*. 2016;16(1):147.
 29. Hagel S, Makarewicz O, Hartung A, et al. ESBL colonization and acquisition in a hospital population: The molecular epidemiology and transmission of resistance genes. *PloS one*. 2019;14(1).
 30. Ben-Ami R, Rodríguez-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum β -lactamase-producing Enterobacteriaceae in nonhospitalized patients. *Clinical Infectious Diseases*. 2009;49(5):682-90.
 31. Zhao R, Shi J, Shen Y, et al. Phylogenetic distribution of virulence genes among ESBL-producing uropathogenic *Escherichia coli* isolated from long-term hospitalized patients. *Journal of clinical and diagnostic research: JCDR*. 2015; 9(7):1.
 32. Bajpai T, Pandey M, Varma M, et al. Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital. *Avicenna journal of medicine*. 2017;7(1):12.
 33. Kaur M and Aggarwal A. Occurrence of the CTX-M, SHV, and the TEM genes among the extended-spectrum β -lactamase producing isolates of Enterobacteriaceae in a tertiary care hospital of North India. *Journal of clinical and diagnostic research: JCDR*. 2013;7(4):642
 34. Pérez CD-A, López-Fresneña N, Carlavilla ALR, et al. Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in *Klebsiella pneumoniae*: a prevalence survey in a Spanish University Hospital. *BMJ Open*. 2019;9(3): 24879.
 35. Valverde A, Coque TM, Sánchez-Moreno MP, et al. Dramatic increase in the prevalence of fecal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae during non-outbreak situations in Spain. *Journal of clinical microbiology*. 2004;42(10):4769-75.
 36. Ahmed SF, Ali MM, Mohamed ZK, et al. Fecal carriage of extended-spectrum β -lactamases and AmpC-producing *Escherichia coli* in a Libyan community. *Annals of clinical microbiology and antimicrobials*. 2014;13(1):22.
 37. Hazirolan G, Mumcuoglu I, Altan G, et al. Fecal Carriage of Extended-spectrum Beta-lactamase and AmpC Beta-lactamase producing Enterobacteriaceae in a Turkish Community. *Nigerian Journal of clinical practice*. 2018;21(1):81-6.